Submitted for Publication: October 30, 2012; final revision received February 13, 2013; accepted February 17, 2012.
Published Online: June 27, 2013. doi:10.1001/jamaophthalmol.2013.4154.
Acquisition of data: S. B. Bressler and Grover.
Analysis and interpretation of data: S. B. Bressler, Qin, Melia, N. M. Bressler, Beck, and Chan.
Drafting of the manuscript: S. B. Bressler, Qin, and N. M. Bressler.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Qin and Melia.
Obtained funding: N. M. Bressler.
Administrative, technical, and material support: N. M. Bressler, Chan, and Grover.
Study supervision: S. B. Bressler, Melia, N. M. Bressler, Beck, and Grover.
Conflict of Interest Disclosures: A complete list of all DRCR.net investigator financial disclosures can be found at http://www.drcr.net.
Funding/Support: This study was supported through a cooperative agreement from the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, US Department of Health and Human Services grants EY14231, EY14229, and EY18817.
Role of the Sponsors: The funding organization (National Institutes of Health) participated in oversight of the conduct of the study and review of the manuscript but not directly in the design or conduct of the study; in the collection, management, analysis, or interpretation of the data; or in the preparation of the manuscript. Allergan Inc provided the triamcinolone and Genentech Inc provided the ranibizumab. As per the DRCR.net Industry Collaboration Guidelines (available at http://www.drcr.net), the DRCR.net had complete control over the design of the protocol, ownership of the data, and all editorial content of presentations and publications related to the protocol. Allergan Inc has provided unrestricted funds to DRCR.net for its discretionary use, and Genentech Inc has provided funds restricted to DRCR.net clinical sites.